Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The midazolam + sufentanil combination is a sedative and analgesic drug combination commonly used for conscious sedation during medical procedures, particularly bronchoscopy. This combination has been studied extensively for its safety and efficacy profile. Midazolam is a benzodiazepine that works by slowing activity in the brain to allow relaxation and decreased consciousness. It produces sedative, anxiolytic, and amnestic effects, making it useful for procedural sedation. Sufentanil is a potent synthetic opioid analgesic that provides pain relief during procedures. When combined with midazolam, it creates a synergistic effect that enhances sedation while providing effective analgesia. The combination has been shown to inhibit the expression of HMGB1 and NF-κB, thereby inhibiting inflammation and improving sedative and analgesic effects. The primary use is for conscious sedation during bronchoscopy and other endoscopic procedures. It has shown superior efficacy compared to either drug alone, leading to higher procedure success rates, better patient and physician satisfaction, and shorter procedure durations. The combination has demonstrated a favorable safety profile with low incidence of conscious sedation-related adverse events and potential anti-inflammatory effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Midazolam + Sufentanil.